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Abstract: Thrombocytopenia is a well recognized complication of infections, including those 
from hepatotropic viruses. Thrombocytopenia may actually be the only manifestation of vital 
hepatitis,  which  should  therefore  be  considered  in  the  differential  diagnosis  of  primary 
immune thrombocytopenia (ITP). 
hepatitis  vary  widely  depending  on  the  specific  infectious  agent  and  the  severity  of  liver 
disease.  Most  of  the  studies  have  described  thrombocytopenia  in  association  with  chronic 
hepatitis C virus (HCV) infection, the most common cause of chronic infection worldwide. 
Studies have shown that treatment of HCV infection often results in substantial improvement 
or complete recovery of the thrombocytopenia. In patients with thrombocytopenia associated 
with HCV-related chronic liver disease, the use of eltrombopag, a thrombopoietin receptor 
agonist, normalizes platelet levels thereby permitting the initiation of antiviral therapy. 
Introduction: Thrombocytopenia, either alone or in 
combination with other hematologic abnormalities, 
is  commonly  associated  with  infectious  diseases
However,  only  a  few  studies  have  specifically 
investigated  this  condition  in  patients  with  viral 
hepatitis
1. 
The  onset  of  the  thrombocytopenia  is  rarely 
abrupt  and  severe  during  acute  viral  hepatitis  A 
(HAV)
2-5, B (HBV)
5-7, C (HCV)
6 and E (HEV)
This appears to have a course similar to that of the 
thrombocytopenia  associated  with  self
infections in children, such as varicella, rubella, or 
mumps
7. It is, at least in part, mediated by immune 
complexes  and  generally  resolves 
within  2  to  8  weeks.  In  occasional  individuals  it 
may  persist  for  months  before  remitting.  Virus
associated  hemophagocytic  syndrome  has  been 
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Thrombocytopenia may actually be the only manifestation of vital 
titis,  which  should  therefore  be  considered  in  the  differential  diagnosis  of  primary 
immune thrombocytopenia (ITP). The mechanisms of thrombocytopenia associated with viral 
hepatitis  vary  widely  depending  on  the  specific  infectious  agent  and  the  severity  of  liver 
Most  of  the  studies  have  described  thrombocytopenia  in  association  with  chronic 
HCV) infection, the most common cause of chronic infection worldwide. 
Studies have shown that treatment of HCV infection often results in substantial improvement 
or complete recovery of the thrombocytopenia. In patients with thrombocytopenia associated 
related chronic liver disease, the use of eltrombopag, a thrombopoietin receptor 
agonist, normalizes platelet levels thereby permitting the initiation of antiviral therapy. 
Thrombocytopenia, either alone or in 
combination with other hematologic abnormalities, 
is  commonly  associated  with  infectious  diseases
1. 
However,  only  a  few  studies  have  specifically 
investigated  this  condition  in  patients  with  viral 
The  onset  of  the  thrombocytopenia  is  rarely 
cute  viral  hepatitis  A 
and E (HEV)
9-11. 
This appears to have a course similar to that of the 
thrombocytopenia  associated  with  self-limiting 
such as varicella, rubella, or 
t is, at least in part, mediated by immune 
resolves  spontaneously 
within  2  to  8  weeks.  In  occasional  individuals  it 
may  persist  for  months  before  remitting.  Virus-
associated  hemophagocytic  syndrome  has  been 
reported in several cases of HAV infection
rarely  in  association  with  HBV  and  HCV 
infections
12-14.
On  the  other  hand,  persistent  thrombo
cytopenia is more typically associated 
infection from HBV or HCV. Despite chronic HBV 
infection  is  still  highly  endemic  in  areas  such  as 
South East Asia and Africa
data  about  HBV  and  thrombocytopenia.  In  one 
study  in  treatment-naïve  patients  with  chronic 
hepatitis B, thrombocytopenia (defined as a platelet 
counts below 150 x 10
9/l) was observed in 17.7% of 
219  patients  with  chronic  active  hepatitis  B  and 
10.6% of 123 HBV inactive carriers
HBV infection with interferon
also  frequently  complicated  with  thrombo
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of HAV infection
8-11, and 
rarely  in  association  with  HBV  and  HCV 
On  the  other  hand,  persistent  thrombo-
cytopenia is more typically associated with chronic 
fection from HBV or HCV. Despite chronic HBV 
infection  is  still  highly  endemic  in  areas  such  as 
South East Asia and Africa
15, there is a paucity of 
data  about  HBV  and  thrombocytopenia.  In  one 
naïve  patients  with  chronic 
nia (defined as a platelet 
/l) was observed in 17.7% of 
219  patients  with  chronic  active  hepatitis  B  and 
10.6% of 123 HBV inactive carriers
16. Treatment of 
n with interferon-alpha (IFN-alpha) is 
also  frequently  complicated  with  thrombo-Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
cytopenia, which in some series has been described 
in over 60% of cases
17. 
However,  most  of  the  recent  literature 
pertaining  to  thrombocytopenia  is  about  chronic 
hepatitis C, which will be the focus of our review.
Natural History of HCV Infection: HCV is now 
recognized  as  the  most  common  viral  infection 
causing chronic liver disease in  humans. The  3rd 
National Health and Nutrition Examination Survey 
(NHANES  III)  estimated  that  nearly  3.2  million 
persons  in  the  general  population  of  the  United 
States  are  infected  with  HCV
18.  Worldwide,  an 
estimated  145  million  individuals  (2.2%  of  the 
world’s  population)  are  infected
19.  HCV  infection 
evolves  towards  a  chronic  state  in  approximately 
85% of patients as demonstrated by the persistence 
of  HCV-RNA  in  serum
20.  However,  severe  and 
long-term complications of chronic HCV infection 
such as liver cirrhosis, end-stage liver disease, and 
hepatocellular  carcinoma  develop  only  in  a 
proportion of infected patients, after a period that 
can exceed 10 to 20 years
21. Chronic HCV infection 
has  also  been  reported  to  be  associated  with  the 
development  of  several  extrahepatic  alterations, 
including thrombo-cytopenia
22. 
Hcv - Associated Thrombocytopenia. 
Epidemiology: Table 1 summarizes the results on 
the prevalence of HCV infection from several cross-
sectional  studies  in  adult  patients  fulfilling  the 
diagnostic  criteria  for  immune  thrombocytopenia 
(ITP)  of  the  American  Society  of  Hematology 
(ASH)
23.  Altogether,  serologic  evidence  of  HCV 
infection was found in 159 of 799 (20%) cases. The 
major  series  published  to  date  evaluated  250 
patients
23.  A  positive  serology  was  found  in  76 
(30%) of these patients. 
While retrospective studies
24,25 suggest that the 
prevalence of ITP among HCV patients is greater 
than would be expected by chance, the prevalence 
of HCV-positive ITP patients in some cohorts may 
be indirectly related to the background prevalence 
of  HCV  infection  reported  in  the  general 
populations
23,26-28.  Chiao et  al  calculated  the 
incidence rate of ITP among 120,691 HCV-infected 
and 454,905 matched HCV-uninfected US veterans 
who received diagnoses during the period 1997 to 
2004
29. Their results indicate that HCV infection is 
actually  associated  with  an  elevated  risk  of 
developing ITP (HR, 1.8; 95% CI, 1.4-2.3) among 
both  untreated  and  treated  patients.  Pockros  et  al 
retrospectively identified 7 ITP cases among 3440 
new HCV patients seen over a 56-month period
24. 
They estimated that the prevalence of CITP among 
their HCV patients was much greater than would be 
expected  by  chance  (P  <  .00001).  Even  in  the 
presence of active liver disease, patients with HCV 
infection  present with  lower  platelet counts  when 
compared with patients with HBV or alcoholic liver 
disease
23,25. Thrombocytopenia either pre-exists and 
prevents the initiation of treatment with pegylated 
interferon (PEG-IFN) or develops as a consequence 
of PEG-IFN treatment, leading to dose modification 
in  19%  of  cases  and  discontinuation  in  2%  of 
cases
30. In patients with cirrhosis, thrombocytopenia 
complicates  antiviral  treatment  much  more 
frequently  than  in  patients  with  HCV  infection 
without cirrhosis
31.
Table 1. Prevalence of HCV infection in adult ITP patients.
Total Number of
Authors number infected (%)
Pawlotsly et al. (1995)
51 139* 14 (10)
Pivetti et al. (1996)
28 33 12 (36)
Garcia-Suarez et al (2000)
26 51 13 (22)
Sakuraya et al (2002)
50 79 11 (14)
Zhang et al. (2003)
27 247 33 (13)
Rajan et al (2005)
23 250 76 (30)
Total 799 159 (20)
*Seven patients of this series had an associated autoimmune 
disorder. Study only included patients with platelet counts of 
less than 25x10
9/L
Pathophysiology:  A  variety  of  pathogenic 
mechanisms  are  reported  to  be  implicated  in 
thrombocytopenia related to chronic HCV infection. 
These include: 1) sequestration of platelets in the 
enlarged  spleen  secondary  to  portal  hypertension 
(hyper-splenism); 2) reduced hepatic production of 
thrombopoietin;  3)  bone  marrow  suppression  by 
HCV  or  antiviral  treatment;  and  4)  increased 
platelet  destruction  mediated  by  immune 
mechanisms  involving  anti-platelet  autoantibodies 
and platelet-associated immune complexes. 
- 1)  Hypersplenism  is  a  common  finding  in 
patients  with  advanced  liver  disease  (especially 
cirrhotic patients), who develop portal hypertension 
ultimately  resulting  in  an  enlarged  spleen  and 
subsequent  platelet  sequestration.  The  increased 
portal pressure causes redistribution of blood to the 
spleen,  subsequent  pooling  of  platelets,  and  the 
increased  clearance  of  platelets  from  the 
circulation
32.  There  is  an  inverse  correlation 
between spleen size and platelet count in patients Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
with  chronic  liver  disease,  the  vast  majority  of 
whom  have  HCV  infection
33,34.  However,  splenic 
platelet  pooling  does  not  fully  account  for  the 
occurrence  of  thrombocytopenia  in  chronic  liver 
disease. In fact, approximately one third of patients 
with  splenomegaly  have  normal  platelet  counts
34, 
hypersplenism is not a consistent finding in patients 
with  HCV-positive  patients  with 
thrombocytopenia
26,35,  spleen  volume  and  platelet 
count have not been closely correlated in cirrhotic 
patients  with  end-stage  liver  disease  and 
thrombocytopenia
36,  and  thrombocytopenia  has 
been  shown  to  persist  after  surgical  portal 
decompression in cirrhotic patients
37,38. 
- 2)  Reduced  hepatic  production  of  the 
thrombopoietin  (TPO)  may  be  one  of  the 
contributing  causes  of  thrombocytopenia  during 
chronic liver diseases. TPO, the growth factor that 
primarily regulates megakaryocyte  maturation and 
platelet  formation,  is  produced  mainly  by 
hepatocytes, and is normally released at a constant 
rate into the circulation
39. Circulating TPO binds to 
the  TPO  receptor  (also  referred  to  as  c-Mpl)  on 
hematopoietic  stem  cells  and  on  megakaryocytes, 
and promotes all stages of platelet production, from 
early  megakaryocyte  proliferation to  mega-
karyocytic maturation and platelet formation. TPO 
also  binds  to  platelets  and  enhances  platelet 
activation and function. In turn, platelets not only 
bind  TPO,  but  also  internalize and degrade TPO. 
Thus, serum levels of TPO are normally regulated 
by  the  total  platelet  mass,  including  platelets 
sequestered  in  the  spleen,  rather  than  by  the 
production rate of TPO
39. Under normal conditions, 
if  platelet  production  decreases,  the  circulating 
platelet count subsequently falls, less TPO is bound 
to  platelets,  and  consequently  the  plasma  TPO 
concentration  increases.  As  a  result, 
megakaryocytopoiesis  increases  to  restore  platelet 
homeostasis,  resulting  in  more  platelets  produced 
and  released.  Once  the  platelet  count  increases, 
excess TPO is bound by circulating platelets, and 
TPO levels decrease to normal levels. However, in 
patients with extensive liver cirrhosis and⁄or fibrosis 
and  subsequent  reduction  in  functioning 
hepatocytes  (clinically  manifested  as  severe 
impairment of liver function),  production of TPO 
can be reduced
34,40. Studies have demonstrated an 
inverse correlation between serum TPO levels and 
liver  fibrosis  grade  (r  =  0.50;  P  <  0.0001),  with 
thrombocytopenia occurring with greater frequency 
and  severity  in patients  with  grade  3  or  4  liver 
fibrosis  than  in  those  with  grades  0–2  liver 
fibrosis
34,40. A correlation between low TPO serum 
level  and  decreases  in  global  liver  function  (r  = 
0.52; P = 0.01) has also been demonstrated
40. One 
study  of  thrombocytopenic  patients  with  cirrhotic 
liver  disease  demonstrated  a  reduction  in  platelet 
production in the bone marrow in the presence of 
low blood TPO levels
41. This finding suggests that 
the  bone  marrow  of  such  patients  may  produce 
fewer  platelets  because  of  decreased  TPO  levels, 
resulting  in  thrombocytopenia.  Furthermore,  after 
successful orthotopic liver transplantation, when the 
dysfunctional  liver  is  replaced  by  a  functioning 
organ,  plasma  TPO  levels  increase,  followed  by 
increased  platelet  production  and  by  an 
improvement  in  thrombocytopenia
36,42.  Increased
degradation  of  TPO,  mediated  by  the  binding  of 
TPO to platelets sequestered in the enlarged spleen, 
may also contribute to thrombocytopenia in patients 
with  cirrhosis.  Serum  TPO  levels  and  platelet 
counts  can  increase  significantly  after  partial 
splenic embolization and the normal physiological 
relationship  between  TPO  and  platelet  count  has 
been  restored  following  this  procedure
43.  Serum 
TPO levels in patients with chronic liver disease do 
not reflect TPO production because of the complex 
interactions  between  TPO  production,  TPO 
degradation,  platelet  turnover  and 
thrombocytopenia. In this patient population, serum 
TPO levels have been variously reported to be low, 
normal  or  elevated,  in  the  presence  of 
thrombocytopenia,  without  close  correlation 
between  TPO  and  platelet counts
43,44.  In contrast, 
patients with high grade (grades 3–4) liver fibrosis 
have significantly lower  TPO levels  than  patients 
with less severe fibrosis (liver fibrosis grades 0–2), 
reflecting decreased production of the TPO by the 
damaged liver
34. 
- 3) Impaired production of platelets secondary 
to  HCV  infection  is  thought  to  be  a  contributing 
factor in the development of thrombocytopenia. In a 
study using reticulated platelets in peripheral blood 
as a marker of thrombopoiesis, patients with liver 
cirrhosis  had  low  platelet  production
41.  Also,  the 
decrease  in  HCV  viral  load  following  interferon
(IFN)-alpha  treatment  correlates  with  significant 
increases  in  platelet  count
24 in  the  absence  of 
hypersplenism  or  serological  evidence  of  platelet 
autoantibodies in some cases
26. Finally, recent data 
on  short-term  CFU-MK  assays  in  patients  with 
chronic hepatitis C showed an evident depression in 
the number of colony-forming unit-megakaryocyte 
(CFU-meg). The whole of these data suggest that 
HCV can directly affect megakaryopoiesis. 
However,  antiviral therapy is  itself  associated 
with  thrombocytopenia.  IFN  admin-istration  can Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
induce a rapid and sustained reduction in peripheral 
platelet  count.  Peck-Radosavljevic  and  colleagues 
demonstrated that  the  platelet count  decreased by 
nearly 28% in subjects treated with at least one dose 
of standard IFN and pegylated interferon (PEG)
45. 
They  also  found  that  despite  a  corresponding 
increase  in  serum  TPO  levels,  the  reticulated 
platelet count did not change or actually decreased 
among  subjects  continuously  exposed  to  PEG. 
These data indicate that bone marrow suppression, 
rather than increased platelet consum-ption, is the 
primary  mechanism  responsible  for  IFN-related 
thrombocytopenia.  Interestingly,  IFN-alpha 
treatment  may  also  suppress  the  production  or 
secretion of TPO
45. Concomitant ribavirin therapy 
appears  to  have  a  protective  effect  against  IFN-
induced reductions in platelet count. In randomized 
controlled trials of PEG with or without ribavirin 
(RBV), the median decrease in platelet count was 
smaller  among  those  receiving  RBV  therapy 
compared with those receiving only PEG
45. Overall, 
in  such  trials,  severe  grade  4  thrombocytopenia 
(less than 20 x 10
9/l) was not observed, and platelet 
counts  less than  50  x 10
9/l  rarely  were observed. 
Current  guidelines  therefore  recommend  the 
management of mild-to-moderate thrombocytopenia 
with PEG dose reduction and the discontinuation of 
HCV therapy in cases of severe thrombocytopenia, 
which  typically  is  seen  only  in  the  setting  of 
cirrhosis. 
- 4) Although there is  a higher prevalence of 
thrombocytopenia  and  anti-platelet  antibodies  in 
patients with liver disease caused by HCV than in 
patients with hepatitis B infection
25, the pathogenic 
significance  of  anti-platelet  antibodies  is 
uncertain
46.  Using  a  direct  monoclonal  antibody-
specific  immobilization  of  platelet  antigen  assay 
(MAIPA), detectable platelet antibodies were found 
in  32  of  48  (66%)  HCV-infected  individuals  at 
various  stages  of  disease
46.  The  most  common 
target  was  glycoprotein  IIb/IIIa,  but  all  other 
glycoproteins were also targets. However, platelet 
autoantibodies lack specificity and do not assist in 
the  diagnosis  of  immune  thrombocytopenia. 
Recently, however, the pathogenetic role of platelet 
antibodies has been supported by an elegant study 
showing  that HCV  core  envelope  1  can  induce 
thrombocytopenia  by  molecular  mimicry  with  an 
epitope  on  platelet  surface  integrin  GPIIIa, 
GPIIIa49-66
47.
Other studies have shown that HCV-RNA can 
be  detected  in  washed  platelets  of  infected 
individuals,  particularly  if  thrombocytopenic
48. 
Furthermore,  there  is  a  non-saturable  binding  of 
HCV to platelets
49. High affinity binding of HCV to 
platelet membrane with subsequent binding of anti-
HCV antibody could theoretically lead to “innocent 
bystander”  phagocytosis  of  platelets
49.  The 
improvement of thrombocytopenia after successful 
interferon therapy supports this kind of mechanism. 
Clinical manifestations:  In one study from Japan
50
the  platelet counts  in  HCV-positive  patients  were 
lower than in the HCV-negative patients (26  9 vs
49  30 x 10
9/l, respectively; P<0.02). Conversely, 
in an American study carried out in the Los Angeles 
area
23,  fewer  HCV-positive  patients  had  severe 
thrombocytopenia, defined as platelet count ≤10 x 
10
9/l (4% vs. 46% for ITP, P≤0.001). However, 56 
(74%)  patients  had  a  platelet  count  ≤50  x  10
9/l. 
Symptoms and signs of thrombocytopenia were less 
frequent in HCV-positive ITP, but major bleeding 
was  more  frequent  (25%  vs.  10%,  P=0.0059). 
Serum cryoglobulins and anticardiolipin antibodies 
were more frequent in HCV-positive ITP (90% and 
62%  respectively),  but  rare  in HCV-negative  ITP 
(7%  and  15%,  P≤0.001  compared  with  HCV-
positive ITP). In the French
51 and Chinese
27 studies 
the characteristics of ITP in HCV-positive patients 
did not differ from HCV-negative ones. 
Treatment: Most case series of patients with HCV 
infection  and  chronic  immune  thrombo-cytopenia 
have reported a greater than 50% platelet response 
to steroids
23,24,52,53. Only in the study from Sakuraya 
et al none of the 10 HCV-positive patients treated 
with prednisolone achieved a response
50. Response 
to splenectomy was not found to differ significantly 
between HCV-positive and HCV-negative patients 
in  two  studies  describing  patients  with  chronic 
ITP
27,50. 
Rajan et al noted that only a minority of HCV-
positive patients received some form of treatment 
for thrombocytopenia [29 (38%) vs. 158 (91%) for 
HCV-negative ITP]
23. Of the seven patients treated 
with prednisone (4 responded, 57%), six developed 
elevations of hepatic transaminases of greater than 
twice  pretreatment  levels  while  receiving 
prednisone.  All  six  patients  had  a  documented 
increase in HCV viral load. Two patients developed 
elevated  serum  bilirubin  levels,  with  one  patient 
developing  overt  jaundice.  Treatment  with  either 
intravenous immunoglobulin (IVIG) or anti-RhD Ig 
proved  effective  in  increasing  platelet  counts  in 
both  the  HCV  seropositive  and  seronegative 
patients. Of five HCV-positive patients treated with 
interferon-alpha  (IFN-α),  four  responded  with 
increased  platelet  counts.  Responders  to  IFN-α 
could be distinguished from the non-responder by a Medit J Hemat Infect Dis 2009, 1(3), Open Journal System 
decrease  in  HCV  quantitative  RNA,  hepatic 
transaminases and cryoglobulins
54. 
In the report of Garcia-Suarez et al each of 6 
HCV patients treated with IFN-α responded with a 
significant  increase  in  platelet  count
26.  Iga  et  al 
reported significant increases in the platelet counts 
of  12  HCV  infected  patients  who  were  complete 
responders  to  interferon  alpha  (IFN-α)  treatment, 
but  no  improvement  in  the  platelet  counts  of  11 
patients who failed IFN-α therapy assessed by viral 
load
35.
Considering  the  results  of  these  various 
studies
26,35,54,  approximately  half  HCV-positive 
adult  ITP  patients  treated  with  IFN-α  responded 
with a rise in platelet count. 
Research  has  focused  on  developing 
compounds specifically to stimulate thrombopoietin 
(TPO)  activity  in  order  to  prevent  or  treat 
thrombocytopenia  in  chronic  liver  diseases. 
Eltrombopag  is  a  small-molecule  nonpeptide  oral 
platelet growth factor that acts as an agonist to the 
thrombopoietin-receptor
55. A phase II multi-center, 
randomized  trial  of  daily  eltrombopag  in  patients 
with  HCV-associated  thrombocytopenia  and 
compensated  liver  disease  showed  that  after  4 
weeks of therapy platelet count increased to ≥100 x 
10
9/L  in  75%,  79%,  and  95%  of  patients  treated 
with  30  mg,  50  mg,  and  75  mg  eltrombopag, 
respectively,  compared to  no  response in  placebo 
patients (P < 0.001) 
56. Significantly more patients 
in  the  eltrombopag  treatment  groups  (36%,  53%, 
and 65% in the 30-mg, 50-mg, and 75-mg groups) 
completed 12 weeks of antiviral therapy compared 
with  6%  of  placebo  patients  and  75%  of  these 
patients had platelet counts above baseline values at 
the end of the antiviral treatment phase. The most 
common adverse event during the initial 4 weeks 
was headache, reported in 36%, 16%, and 17% of 
patients who received 30 mg of eltrombopag, 50 mg 
of  eltrombopag,  and  75  mg  of  eltrombopag, 
respectively,  as  well  as  in  17%  of  patients  who 
received  placebo.  Thereafter,  the  adverse  events 
were those expected with interferon-based therapy 
(influenza-like  illness,  fatigue,  chills,  and 
headache). 
Since  eltrombopag  has  shown  remarkable 
activity in chronic ITP as well
57, this agent appears 
to be an adequate candidate for the management of 
HCV-related chronic thrombocytopenia.
Conclusions: Both acute and chronic viral hepatitis 
may be associated with isolated thrombocytopenia 
and  should  be  considered  in  the  differential 
diagnosis of ITP when isolated thrombocytopenia is 
present.  Most  of  the  studies  have  described 
thrombo-cytopenia in association with chronic HCV 
infection, by far the most common cause of chronic 
hepatitis.  Several  potential  mechanisms  can 
contribute to the thrombocytopenia in chronic HCV 
infection,  including  accelerated  platelet  clearance 
due to immune complex disease, cross-reactivity of 
anti-platelet  glycoprotein  antibodies  and  viral  or 
bacterial  antibodies,  defective  platelet  production, 
and splenic sequestration of platelets secondary to 
portal  hypertension  and  decreased  production  of 
thrombopoietin.
Serologic  evaluation  for  HCV  infection  is 
indicated  in  patients  with ITP  because  of  the 
potential adverse effect of prolonged corticosteroid 
usage on the underlying infection and the utility of 
antiviral therapy in treating the both the underlying 
infection and the thrombocytopenia. Treatment with 
eltrombopag,  a  second  generation  thrombopoietin 
receptor agonist, appears to be very efficacious in 
elevating  the  platelet  count  and  is  well  tolerated. 
Ongoing phase III studies in HCV-related chronic 
thrombocytopenia will better define the benefits of 
this agent compared to standard of care. 
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